Contribute Try STAT+ Today

WASHINGTON — President Trump on Tuesday called on the Food and Drug Administration to speed the approval of drugs to treat life-threatening diseases, deriding the agency’s current process as “slow and burdensome.”

In an address to a joint session of Congress, Trump said that the FDA approval process “keeps too many advances … from reaching those in need.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Do not relieve drug makers of the burden of proving their products are efffective and safe. Yes, thalidomide, also Framingham compounding lab. I do not want to be a test animal!

  • Approving Cempra’s solithromycin (an antibiotic) without requiring the extra financially burdensome safety studies the FDA asked for in December (the company just laid off about 67% of their personnel due to this unexpected demand) could be one of the very first “quick wins” that the Trump administration can rapidly accomplish.

    For more info, see: “Cempra’s Solithromycin And The Great FDA Echo Chamber”, on Seeking Alpha. (An account is needed past the first page.)

    • So, you would rather the public complete the safety studies for Cempra by consuming an inadequately characterised drug? I would add that potential hepatotoxicity is not a trifling thing.

Comments are closed.